SignalXSignalX

ACTU ACTUATE THERAPEUTICS, INC.

Q3 2025 10-Q
Filed: Nov 13, 2025Period ending Sep 30, 2025
Health Care
Pharmaceutical PreparationsSEC EDGAR
ACTUATE THERAPEUTICS, INC. Overview

ACTUATE THERAPEUTICS, INC. (ACTU) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 13, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q3 2025 10-Q

Risk Factors

  • • No new or materially updated risk factors disclosed compared to most recent 10-K
  • • Regulatory risk: ongoing compliance with FDA and global regulatory bodies remains critical for product approvals
+2 more insights

Quarterly Financial Summary
XBRL

Net Income

-$5M

ROE

-49.4%

Total Assets

$18M

Source: XBRL data from ACTUATE THERAPEUTICS, INC. Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.

Get deeper insights on ACTUATE THERAPEUTICS, INC.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.